NYSE · Healthcare · Drug Manufacturers—General
Eli Lilly and Company (LLY)
As of Sep 25, 4:03 PM ET, Eli Lilly and (LLY) last traded at $1,183.46, up 0.13% on the day. Its TickerHum research score is 69/100 (above average). It reported revenue of $79.67B for the twelve months ending 2026-06-30, up 49.6% year over year.
Ratings
- Valuation: 37/100 — Strongest input: price / earnings (ttm) 39.7x. Weakest: price / sales (ttm) 14.0x.
- Growth: 100/100 — Based on revenue growth (ttm, yoy) +49.6 %, diluted eps growth (ttm, yoy) +94.7 %.
- Profitability: 100/100 — Based on net margin 33.5 %, return on equity 78.8 %.
- Financial health: 31/100 — Strongest input: long-term debt / equity 1.41. Weakest: cash / long-term debt 0.19.
- Momentum: 76/100 — Strongest input: 1-year return +63.3 %. Weakest: 3-month return -2.0 %.
- Attention: 55/100 — Strongest input: headlines in the last 7 days 48. Weakest: volume vs 3-month average 0.7x.
- Risk: 68/100 — Strongest input: annualised volatility (1y) 35.4 %. Weakest: max drawdown (1y) -23.3 %.
- Data confidence: 87/100 — Strongest input: latest financial period age (days) 56 d. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $79.67B | TTM ending 2026-06-30 · 10-Q |
| Revenue growth | 49.6% | TTM ending 2026-06-30 · 10-Q |
| Net income | $26.71B | TTM ending 2026-06-30 · 10-Q |
| Diluted EPS | $29.79 | TTM ending 2026-06-30 · 10-Q |
| Net margin | 33.5% | TTM ending 2026-06-30 · 10-Q |
| Cash | $8.95B | as of 2026-06-30 · 10-Q |
| Long-term debt | $47.86B | as of 2026-06-30 · 10-Q |
| Debt / equity | 1.41 | as of 2026-06-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000059478).
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.